| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minireview |
Department of Physiology (L.H.), Faculty of Medicine, Semmelweis University, H-1444 Budapest, Hungary; and Endocrinology and Reproduction Research Branch (K.J.C.), National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-4510
Address correspondence and requests for reprints to: Kevin J. Catt, Endocrinology and Reproduction Research Branch, National Institute of Child Health and Human Development, Building 49, Room 6A36, National Institutes of Health, Bethesda, Maryland, 20892-4510. E-mail: cattk{at}mail.nih.gov.
Angiotensin II (Ang II) activates a wide spectrum of signaling responses via the AT1 receptor (AT1R) that mediate its physiological control of blood pressure, thirst, and sodium balance and its diverse pathological actions in cardiovascular, renal, and other cell types. Ang II-induced AT1R activation via Gq/11 stimulates phospholipases A2, C, and D, and activates inositol trisphosphate/Ca2+ signaling, protein kinase C isoforms, and MAPKs, as well as several tyrosine kinases (Pyk2, Src, Tyk2, FAK), scaffold proteins (G protein-coupled receptor kinase-interacting protein 1, p130Cas, paxillin, vinculin), receptor tyrosine kinases, and the nuclear factor-
B pathway. The AT1R also signals via Gi/o and G11/12 and stimulates G protein-independent signaling pathways, such as ß-arrestin-mediated MAPK activation and the Jak/STAT. Alterations in homo- or heterodimerization of the AT1R may also contribute to its pathophysiological roles. Many of the deleterious actions of AT1R activation are initiated by locally generated, rather than circulating, Ang II and are concomitant with the harmful effects of aldosterone in the cardiovascular system. AT1R-mediated overproduction of reactive oxygen species has potent growth-promoting, proinflammatory, and profibrotic actions by exerting positive feedback effects that amplify its signaling in cardiovascular cells, leukocytes, and monocytes. In addition to its roles in cardiovascular and renal disease, agonist-induced activation of the AT1R also participates in the development of metabolic diseases and promotes tumor progression and metastasis through its growth-promoting and proangiogenic activities. The recognition of Ang IIs pathogenic actions is leading to novel clinical applications of angiotensin-converting enzyme inhibitors and AT1R antagonists, in addition to their established therapeutic actions in essential hypertension.
This article has been cited by other articles:
![]() |
H. Ohtsu, S. Higuchi, H. Shirai, K. Eguchi, H. Suzuki, A. Hinoki, E. Brailoiu, A. D. Eckhart, G. D. Frank, and S. Eguchi Central Role of Gq in the Hypertrophic Signal Transduction of Angiotensin II in Vascular Smooth Muscle Cells Endocrinology, July 1, 2008; 149(7): 3569 - 3575. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Otis, S. Campbell, M. D. Payet, and N. Gallo-Payet In Adrenal Glomerulosa Cells, Angiotensin II Inhibits Proliferation by Interfering with Fibronectin-Integrin Signaling Endocrinology, July 1, 2008; 149(7): 3435 - 3445. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hardel, N. Harmel, G. Zolles, B. Fakler, and N. Klocker Recycling endosomes supply cardiac pacemaker channels for regulated surface expression Cardiovasc Res, July 1, 2008; 79(1): 52 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Eguchi Triple Twist Theory of Rho Inhibition by the Angiotensin II Type 2 Receptor Circ. Res., May 23, 2008; 102(10): 1143 - 1145. [Full Text] [PDF] |
||||
![]() |
S. Nattel, B. Burstein, and D. Dobrev Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications Circ Arrhythmia Electrophysiol, April 1, 2008; 1(1): 62 - 73. [Full Text] [PDF] |
||||
![]() |
Y. Takata, J. Liu, F. Yin, A. R. Collins, C. J. Lyon, C.-H. Lee, A. R. Atkins, M. Downes, G. D. Barish, R. M. Evans, et al. PPAR{delta}-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis PNAS, March 18, 2008; 105(11): 4277 - 4282. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Szidonya, M. Cserzo, and L. Hunyady Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions J. Endocrinol., March 1, 2008; 196(3): 435 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Brili, D. Tousoulis, C. Antoniades, C. Vasiliadou, M. Karali, N. Papageorgiou, N. Ioakeimidis, K. Marinou, E. Stefanadi, and C. Stefanadis Effects of Ramipril on Endothelial Function and the Expression of Proinflammatory Cytokines and Adhesion Molecules in Young Normotensive Subjects With Successfully Repaired Coarctation of Aorta A Randomized Cross-Over Study. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 742 - 749. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Frank, C. Kuhn, B. Brors, C. Hanselmann, M. Ludde, H. A. Katus, and N. Frey Gene Expression Pattern in Biomechanically Stretched Cardiomyocytes: Evidence for a Stretch-Specific Gene Program Hypertension, February 1, 2008; 51(2): 309 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. F Nogueira, C. A Vargas, M. Otis, N. Gallo-Payet, W. B Bollag, and W. E Rainey Angiotensin-II acute regulation of rapid response genes in human, bovine, and rat adrenocortical cells J. Mol. Endocrinol., December 1, 2007; 39(6): 365 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Casal, S. Ryser, A. M. Capponi, and C. F. Wang-Buholzer Angiotensin II-Induced Mitogen-Activated Protein Kinase Phosphatase-1 Expression in Bovine Adrenal Glomerulosa Cells: Implications in Mineralocorticoid Biosynthesis Endocrinology, November 1, 2007; 148(11): 5573 - 5581. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kisfalvi, O. Rey, S. H. Young, J. Sinnett-Smith, and E. Rozengurt Insulin Potentiates Ca2+ Signaling and Phosphatidylinositol 4,5-Bisphosphate Hydrolysis Induced by Gq Protein-Coupled Receptor Agonists through an mTOR-Dependent Pathway Endocrinology, July 1, 2007; 148(7): 3246 - 3257. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Izumi-Nagai, N. Nagai, Y. Ozawa, M. Mihara, Y. Ohsugi, T. Kurihara, T. Koto, S. Satofuka, M. Inoue, K. Tsubota, et al. Interleukin-6 Receptor-Mediated Activation of Signal Transducer and Activator of Transcription-3 (STAT3) Promotes Choroidal Neovascularization Am. J. Pathol., June 1, 2007; 170(6): 2149 - 2158. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Turu, A. Simon, P. Gyombolai, L. Szidonya, G. Bagdy, Z. Lenkei, and L. Hunyady The Role of Diacylglycerol Lipase in Constitutive and Angiotensin AT1 Receptor-stimulated Cannabinoid CB1 Receptor Activity J. Biol. Chem., March 16, 2007; 282(11): 7753 - 7757. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. McAllister-Lucas, J. Ruland, K. Siu, X. Jin, S. Gu, D. S. L. Kim, P. Kuffa, D. Kohrt, T. W. Mak, G. Nunez, et al. CARMA3/Bcl10/MALT1-dependent NF-{kappa}B activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells PNAS, January 2, 2007; 104(1): 139 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Mehta and K. K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kurihara, Y. Ozawa, K. Shinoda, N. Nagai, M. Inoue, Y. Oike, K. Tsubota, S. Ishida, and H. Okano Neuroprotective Effects of Angiotensin II Type 1 Receptor (AT1R) Blocker, Telmisartan, via Modulating AT1R and AT2R Signaling in Retinal Inflammation Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5545 - 5552. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Provoost Does Angiotensin Receptor Recycling Regulate Blood Pressure? Hypertension, September 1, 2006; 48(3): 370 - 371. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |